Farxiga (Dapagliflozin) Dosing
For type 2 diabetes with eGFR ≥45 mL/min/1.73 m², start Farxiga 5 mg daily and increase to 10 mg daily for additional glycemic control; for heart failure, chronic kidney disease, or cardiovascular risk reduction, use 10 mg daily regardless of diabetes status, and continue therapy down to eGFR ≥25 mL/min/1.73 m² for cardiorenal protection even when glycemic benefit is lost. 1
Type 2 Diabetes Mellitus (Glycemic Control)
Standard Dosing
- Starting dose: 5 mg orally once daily 1
- Titration: May increase to 10 mg orally once daily for additional glycemic control 1
- Age range: Adults and pediatric patients ≥10 years 1
Renal Adjustments for Glycemic Control
- eGFR ≥45 mL/min/1.73 m²: No dose adjustment required 1
- eGFR <45 mL/min/1.73 m²: NOT recommended for glycemic control—dapagliflozin is ineffective for glucose lowering at this level due to its mechanism of action 1, 2
- Important caveat: The eGFR threshold of 45 mL/min/1.73 m² applies ONLY to glycemic control indication; cardiorenal protection continues at lower eGFR 2, 1
Heart Failure (HFrEF and HFpEF)
Standard Dosing
- Dose: 10 mg orally once daily 1
- Indication: Reduce risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits in adults with heart failure 1
- Evidence base: Benefits demonstrated in both HFrEF (DAPA-HF, EMPEROR-Reduced) and HFpEF (DELIVER, EMPEROR-Preserved) 3, 4, 5
Renal Adjustments for Heart Failure
- eGFR ≥25 mL/min/1.73 m²: 10 mg daily, same as normal renal function 1
- eGFR <25 mL/min/1.73 m²: Do NOT initiate 1
- If eGFR falls below 25 while on treatment: Continue 10 mg daily to reduce risk of eGFR decline, ESKD, CV death, and heart failure hospitalization 1
Key Clinical Points
- Efficacy is independent of diabetes status—58% of DAPA-HF participants did not have diabetes 3
- Benefits consistent across baseline medical therapy including ARNI, beta-blockers, and mineralocorticoid receptor antagonists 3
- Reduces heart failure hospitalization by approximately 30% and cardiovascular death by 18% 5
Chronic Kidney Disease
Standard Dosing
- Dose: 10 mg orally once daily 1
- Indication: Reduce risk of sustained eGFR decline, ESKD, cardiovascular death, and heart failure hospitalization in adults with CKD at risk of progression 1
Renal Adjustments for CKD
- eGFR ≥25 mL/min/1.73 m²: 10 mg daily 1, 2
- eGFR 20-24 mL/min/1.73 m²: Initiation supported by recent evidence, particularly with albuminuria or heart failure 2, 6
- eGFR <25 mL/min/1.73 m²: Initiation not recommended 1
- If eGFR falls below 25 during treatment: Continue therapy until dialysis is required 1, 6
Evidence and Outcomes
- DAPA-CKD trial enrolled patients with eGFR 25-75 mL/min/1.73 m² and urinary albumin-to-creatinine ratio 200-5000 mg/g 7
- Reduced primary composite outcome (≥50% eGFR decline, ESKD, or renal/CV death) by 39% (HR 0.61) 7
- Benefits consistent with and without type 2 diabetes 7, 8, 9
- Slows eGFR decline rate: -1.09 vs -2.85 mL/min/1.73 m²/year with placebo 10
- Updated KDIGO 2022 and ADA 2022 guidelines now recommend initiation at eGFR ≥20 mL/min/1.73 m² based on DAPA-CKD and EMPEROR trials 2
Cardiovascular Disease Risk Reduction
Standard Dosing
- Dose: 10 mg orally once daily 1
- Indication: Reduce risk of heart failure hospitalization in adults with type 2 diabetes and either established cardiovascular disease or multiple cardiovascular risk factors 1
Clinical Context
- SGLT2 inhibitors (including dapagliflozin) recommended for patients with type 2 diabetes and atherosclerotic cardiovascular disease to reduce heart failure hospitalization and death 3
- Benefits extend to patients aged >50 years with additional cardiovascular risk factors 3
Critical Monitoring and Safety
Pre-Initiation Assessment
- Assess renal function before starting and monitor as clinically indicated 1
- Assess volume status—correct volume depletion before initiating dapagliflozin 1, 2
Expected eGFR Changes
- Reversible eGFR decline occurs after initiation but does NOT require discontinuation 2, 6, 7
- This initial dip reflects hemodynamic changes, not kidney injury 2
- Long-term effect is renal protection with slower eGFR decline 10, 11
Temporary Interruption
- Withhold for ≥3 days before major surgery or procedures with prolonged fasting 1
- Hold during acute illness, prolonged fasting, or critical illness to avoid ketoacidosis 2, 6
- Resume when patient is clinically stable and has resumed oral intake 1
Adverse Events to Monitor
- Genital mycotic infections: Most common, especially in women—counsel on hygiene 2
- Volume depletion: Monitor for hypovolemia; consider proactive diuretic dose reduction in high-risk patients 2
- Diabetic ketoacidosis: Rare but serious—educate on signs/symptoms, maintain at least low-dose insulin in insulin-requiring patients 2
- Hypoglycemia: Adjust background sulfonylureas or insulin as appropriate 2
Contraindications
- History of serious hypersensitivity reaction to dapagliflozin (anaphylaxis, angioedema) 1
- Type 1 diabetes for glycemic control (markedly increased ketoacidosis risk) 1
Dosing Algorithm by Clinical Scenario
Scenario 1: Type 2 Diabetes Without CKD or HF
- eGFR ≥45: Start 5 mg daily, titrate to 10 mg for glycemic control 1
- eGFR <45: Do not use for glycemic control 1
Scenario 2: Type 2 Diabetes With Established CVD or Multiple Risk Factors
Scenario 3: Heart Failure (With or Without Diabetes)
Scenario 4: CKD With Albuminuria (With or Without Diabetes)
- eGFR ≥25: Use 10 mg daily 1, 7
- eGFR 20-24: Consider initiation, especially with albuminuria or heart failure 2, 6
- eGFR <20: Do not initiate; continue if already on therapy until dialysis 1, 6
Common Pitfalls to Avoid
Do not discontinue dapagliflozin when eGFR falls below 45 mL/min/1.73 m² in patients on therapy for heart failure or CKD—the cardiorenal benefits persist down to eGFR 25 and below 1, 2
Do not confuse the eGFR threshold for glycemic control (45 mL/min/1.73 m²) with the threshold for cardiorenal protection (25 mL/min/1.73 m²)—these are different indications with different cutoffs 1, 2
Do not stop dapagliflozin due to initial eGFR decline—this is expected and reversible, reflecting hemodynamic effects rather than kidney injury 2, 6, 7
Do not forget to withhold during sick days, surgery, or prolonged fasting—this reduces ketoacidosis risk 2, 6, 1
Do not overlook volume status assessment—correct dehydration before starting and monitor for volume depletion, especially in elderly patients or those on loop diuretics 2, 1